Navigation Links
Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
Date:2/5/2008

Mylan to Present at Merrill Lynch's Global Pharmaceutical Conference Feb.

5, 2008

PITTSBURGH, Feb. 5 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Wednesday, Feb. 27, 2008, at 10:30 a.m. ET to provide a review of the quarter and nine months ended Dec. 31, 2007. The Company also will provide an operational and integration update on Merck Generics, which the Company acquired on Oct. 2, 2007. The Company will release its financial results before the market opens.

The Company also announced that it will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference today, Feb. 5, at 11:40 a.m. ET. A copy of the Company's slide presentation will be available at http://www.mylan.com.

The dial-in number to access the Feb. 27 call is 877-874-1586 or 719-325- 4814 for international callers. A replay, available for approximately eight days, will be available at 888-203-1112 or 719-457-0820 for international callers, with access pass code 8774583.

To access a live webcast of the Feb. 27 call, please log on to Mylan's Web site (http://www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on http://www.mylan.com for approximately eight days.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
3. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
4. Mylan Sets Date of 2008 Annual Meeting
5. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
6. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
7. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
8. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
9. Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel
10. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
11. Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... office, will speak at the American Conference Institute’s 21st Drug & Medical Device ... a Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical ...
(Date:12/2/2016)... ... 2016 , ... Advanced Inc., a leading provider of travel therapy and travel ... serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served ... and operational leadership experience to Advanced Inc. He began his career in finance at ...
(Date:12/2/2016)... PITTSBURGH, PA (PRWEB) , ... December 02, 2016 , ... ... or struggling through rehabilitation of an injury, patients must find the one that works ... for his pain, he created a machine that worked and decided to share it ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... YORK , December 2, 2016 ... 5,251.11, down 1.36%; the Dow Jones Industrial Average edged 0.36% ... at 2,191.08, down 0.35%. Losses were broad based as six ... Stock-Callers.com has initiated research reports on the following Services equities: ... (NASDAQ: QGEN ), INC Research Holdings Inc. (NASDAQ: ...
(Date:12/2/2016)... , Dec. 1, 2016 Around the ... country, region and each habitable land present over earth. ... every individual once in a life time this is ... care available until now. Given the steady increase in ... together with the spiraling healthcare costs of treatment, there ...
(Date:12/2/2016)... The iShares Nasdaq Biotechnology Exchange-Traded Fund ... victory early in November. Less political risk has boosted ... predicting an uptick in M&A activities. Today, Stock-Callers.com takes ... they have fared at the last close: Celldex Therapeutics ... (NASDAQ: FOLD ), Navidea Biopharmaceuticals Inc. (NYSE ...
Breaking Medicine Technology: